page_title: Grindeks
hierarchical_section_title: Grindeks
caption_attribution_description: Français&#160;: Façade de l'entreprise pharmaceutique Grindeks dans le voisinage de Šķirotava, rue Krustpils à Riga (Lettonie). Photo de Jānis Vilniņš. 2010.
context_page_description: JSC Grindeks, is a Latvian company listed on the Nasdaq Riga with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.
  Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients.
  The company specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
  One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate. Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.
  In 2018, Grindeks turnover reached €145.5 million. Grindeks had 1355 employees.
  Patron of the University of Latvia.
  Grindeks is a bronze patron of the University of Latvia Foundation. In 2004, "Grindeks" donated funds for the modernization of the equipment of the Medical Faculty of the University of Latvia.
context_section_description: JSC Grindeks (branded as Grindex), is a Latvian company listed on the Nasdaq Riga with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.
  Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients.
  The company specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
  One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate. Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.
  In 2018, Grindeks turnover reached €145.5 million. Grindeks had 1355 employees.
  Patron of the University of Latvia.
  Grindeks is a bronze patron of the University of Latvia Foundation. In 2004,  "Grindeks" donated funds for the modernization of the equipment of the Medical Faculty of the University of Latvia.
caption: Main building of the company
exif: {}